How We Do It

Implementation of distress screening in an oncology setting


 

The recommendations of numerous groups, such as the Institute of Medicine and the National Comprehensive Cancer Network, have resulted in the first regulatory standard on distress screening in oncology implemented in 2015 by the American College of Surgeons Commission on Cancer. This practice-changing standard promises to result in better quality cancer care, but presents unique challenges to many centers struggling to provide high-quality practical assessment and management of distress. The current paper reviews the history behind the CoC standard, identifies the most prevalent symptoms underlying distress, and discusses the importance of distress screening. We also review some commonly used instruments for assessing distress, and address barriers to implementation of screening and management.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Immune-related events with checkpoint inhibitors are manageable
MDedge Hematology and Oncology
ASCO: Three-drug combo best for highly emetogenic chemotherapy
MDedge Hematology and Oncology
Childhood, young adult cancer survivors face high risk of long-term morbidity
MDedge Hematology and Oncology
Hold the checkpoint inhibitors when pneumonitis symptoms occur
MDedge Hematology and Oncology
AHA: Older breast cancer patients more likely to die of heart disease than malignancy
MDedge Hematology and Oncology
Review: Opioid prescriptions are the work of many physicians
MDedge Hematology and Oncology
Oncology 2015: new therapies and new transitions toward value-based cancer care
MDedge Hematology and Oncology
Pregnancy did not increase Hodgkin lymphoma relapse rate
MDedge Hematology and Oncology
Early infection-related hospitalization portends poor breast cancer prognosis
MDedge Hematology and Oncology
Filgrastim-sndz debuts as the first biosimilar approved in United States
MDedge Hematology and Oncology